-2%
Trangina MR (Trimetazidine Dihydrochloride)
Metabolic anti-anginal therapy for better heart energy efficiency
Trimetazidine Dihydrochloride is a metabolic anti-ischemic agent and the first 3-ketoacyl-CoA thiolase (KAT) inhibitor.
It works by shifting energy production from fatty acid oxidation to glucose oxidation, allowing the heart to produce more energy using the same amount of oxygen.
This enhances cardiac efficiency, reduces lactic acid buildup, and prevents angina attacks, keeping the heart active and oxygen-efficient.